semaglutide evoke Efficacy and safety of oral 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials semaglutide evoke Weight-loss drug semaglutide

While many associate GLP-1 with popular diabetes or weight loss medications, few understand the powerful role this naturally occurring hormone plays

Broader Implications for Vaccines and Therapies While mimicry explains autoimmune risks, it also emphasizes the need for precision in therapeutic design

A heady combination of influencers, deregulation, GLP-1 success stories and DIY medicine are driving the phenomenal growth in peptides

The definition of a typical GLP-1 user has steadily expanded over the past few years, from diabetics and people with obesity to celebrities looking to drop a few pounds to anyone who can afford the shots

Outcomes included total and early-phase (060min) areas under the curve (AUCs) and peak concentrations

Once-weekly semaglutide 2.4 mg conferred a greater reduction in major adverse cardiovascular events than placebo, regardless of change in body weight, according to an analysis of the SELECT trial published in The Lancet